http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2019176880-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b01dcd61775e996fac631d4b10c4e87f http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_69b5b385097fedde4c187afb1359b1e9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c5073a0063d6be9e25c14d2af0a1ee89 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6851 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-686 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6827 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate | 2019-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f084e93c806280f0be05a5e1ad17adc4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa9ffaeeef4a084104ca4cd0b06e43bb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5a3dd3dccf6a6f2db3555949f2053a55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1bf9b6474de0146f6777d8ec5a529a2f |
| publicationDate | 2019-10-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2019176880-A |
| titleOfInvention | Methods and kits for screening cancer patients |
| abstract | The present invention relates to methods and kits for screening cancer patients, in particular for determining whether cancer patients benefit from anti-tumor treatment. The present invention is a method and kit for determining whether a cancer patient will benefit from anti-tumor treatment. In A i) tumor sample obtained from a patient, 1 illustrating expression levels ELA 1 ~ELA n of one or several genes GA 1 ~GA n shows a human adaptive immune response, and the human immune suppression response one or determining the expression level ELI 1 ~ELI n of several genes GI 1 ~GI n, ii) a step i) the expression level determined in ELA 1 ~ELA n and ELI 1 ~ELI n, predetermined Compared to the reference values ELRA 1 -ELRA n and ELRI 1 -ELRI n (the predetermined reference value is the expression level of the gene and the patient's survival and associated log rank p-value by Kaplan-Meier curve analysis) Iii) the patient is better (beyond the pre-determined reference value), selected to separate the group of cancer patients into two groups Concludes whether the patient has an adaptive immune response of a high level) or poor (a level below a predetermined reference value) and a good or poor immunosuppressive response, optionally further comprising A method for screening cancer patients, comprising the step of determining whether or not it can be advantageously received, a kit comprising components for performing step i), and a responder to anti-tumor treatment according to the present invention. A chemotherapeutic agent, immunotherapeutic agent, or radiation therapy agent for use in the treatment of cancer patients. [Selection figure] None |
| priorityDate | 2012-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 626.